Harald Keller

eWise Group, Inc. provides financial software solutions. It products include money manager, personal data vault, connected insights and resources. The company was founded by Alexander Grinberg in 2000 and is headquartered in Centennial, CO.

Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ.

Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts.

Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million.

ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland.

Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.

Swyx Solutions GmbH develops and provides software based internet protocol telephony solutions. Its products include unified communications and case studies, third party products and SIP-provider. The firm also offers communication software, phones, protocol and update services. The company was founded by Wolfgang Schröder, Ralf Ebbinghaus, Uwe Sauerbrey and Frank Heidemann in 1999 and is headquartered in Dortmund, Germany.

Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany.

Evolva SA is a Swiss-headquartered, international pharmaceutical biotech company focused on the discovery and development of drugs based on its distinctive and proprietary genetic chemistry platform. The company was founded in Switzerland in 2004 based on US/Danish technology. Evolva is headquartered in Allschwil/Basel with operations in Denmark, India and the USA. The Company has raised CHF 38.2 million of equity to date and employs 75 persons of whom 30 are based in Allschwil. The firm's strategy and business approach is based on five pillars that offer a sustainable development path for creating a successful company, which include Building a balanced portfolio. Evolva focuses on orally available small molecules in the belief that they are more convenient for patients and more cost-effective both from manufacture and administration points of view for the society, focus on differentiated pharmaceutical products with major benefits. Focusing on cardiovascular/renal and infectious diseases. Together they cause more than 50% of all deaths worldwide. Most of the top 20 pharmaceutical companies are active in both sectors, and all are active in one of the two sectors - hence widening Evolva's opportunities to partner. Building technology platform as the source of this differentiation. Evolva finds different structures with different properties from those found by the 99% of the industry that focuses on synthetic chemistry or proteins. Openness to unusual markets. The biotech business model has changed. As well as the established markets new opportunities arise in emerging countries such as India and China, and in adjacent sectors such as treatments against potential bio-terrorist and bio-warfare agents and the production of pharmaceutical and industrial chemical intermediates. Cost-effective implementation. Evolva places different functions around the globe according to where local conditions best suit. This approach both reduces Evolva's cost base and increases access to revenues, partners and talent. Evolva sees revenues and partners as important because they provide additional flexibility, resources and talent. Also, they provide important opportunities to better understand, and better meet, the needs of current and future customers.

Cavendish Kinetics, Inc. provides radio frequency tuning solutions for mobile devices in the wireless industry. It is a fabless supplier of tunable components for RF circuits used in cellular handsets, laptops, netbooks, tablets, and other consumer wireless devices. The firm offers tunable RF circuits, based on third-generation RF MEMS technology and its semiconductor processes, let users pack more performance into the same space. The company was founded by Charles Gordon Smith and Hermann M. Hauser in 1994 and is headquartered in San Jose, CA.

Sensimed SA develops non-invasive soft contact lens-based solutions. It offers solutions to monitor fluctuations in intraocular pressure continuously. The company was founded by Matteo Leonardi and Sacha Cerboni in 2003 and is headquartered in Lausanne, Switzerland.

VERTILAS GmbH develops, produces, and distributes laser diodes for optical communications technology, sensor engineering, and measurement methods. The company's products include gas sensing spectroscopy, data and telecommunication applications, spectroscopic diode lasers, and engineering services in the fields of fiberoptics, semiconductors, laser diodes, and vertical cavity surface-emitting laser diodes. The company was founded in December 2001 by Markus Ortsiefer and Markus-Christian Amann and is headquartered in Garching, Germany.

agnion Energy, Inc. supplies local bio-energy plants and specializes in transforming solid biomass into electricity and heat. The firm utilizes its patented Heatpipe-Reformer technology, which enables wood-based biomass to be converted into synthetic gas. Its decentralized plants can both produce synthetic natural gas (SNG) and hydrogen as well as support heat and power cogeneration. The company was founded in 2007 and is headquartered in Wilmington, DE.

GLO AB operates as a holding company. It develops technologies to fabricate defect-free, single-crystal semiconductor nanowire structures, with direct control of morphology and chemical composition. The firm focuses on the development and commercialization of light-emitting diode products using nanotechnology. Its products can be use in display, automotive and illumination application. The company was founded by Lars Ivar Samuelson, Steven Alan Morrell and Jonas Björn Ohlsson on February 25, 2003 and is headquartered in Lund, Sweden.

Sobera Capital GmbH (Sobera Capital) is an independent private equity and venture capital firm founded by Johannes Rabini and Dr. Stefan Beil in 2010. The firm is headquartered in Berlin, Germany.

Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark.

coramaze technologies GmbH operates as a medical device company which develops valve repair system. It offers mitramaze a novel concept for transcatheter mitral valve repair intended for treatment of inoperable patients suffering from severe functional mitral regurgitation. The company was founded by Laura Figulla and Till Neumann in 2013 and is headquartered in Munich, Germany.

NBE-Therapeutics AG operates as biotechnology company. It develops next-generation ADCs improving treatment options for cancer patients. The company was founded by Ulf Grawunder in 2012 and is based in Basel, Swizerland.

ImevaX GmbH develops vaccines against pathogens of chronic infectious diseases, especially helicobacter pylori. It offers diagnostic and therapeutic methods for bacterial agents. The company was founded by Markus Gerhard in 2014 and is headquartered in Munich, Germany.

Immatics US, Inc. develops adoptive cell therapies (ACT) for the treatment of cancer. The company’s ACT therapies are intended to use human T-cells that have been multiplied outside the body before being infused into a cancer patient. It also offers XPRESIDENT, a target discovery engine that enables users to identify, quantify, and prioritize tumor-associated peptides that are recognized by T-cells. The company was founded by Harpreet Singh-Jasuja, Toni Weinschenk, Niels Emmerich, Hans-George Rammensee, Steffen Walter, Peter Brossart and Hansjorg Schild in June 2015 and is headquartered in Houston, TX.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

High-Tech Gründerfonds Management GmbH (HTGF) is a venture capital firm founded in 2005. The firm is headquartered in Bonn, Germany.